Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12)
The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the “Quad compromise” is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry’s ability to...
Read moreKey considerations on the scope, utility and processes around updating the WHO Essential Medicines List
The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.
Read moreNicholas Misso
Nicholas is responsible for the management of IFPMA’s business operations. Working across functions Nicholas oversees legal, program budget management and business process development and supports IFPMA leads in the management of finance, administration and HR workstreams. Before joining IFPMA, Nicholas served as the operations lead for the ‘Access Accelerated – Moving NCD Care Forward’ initiative. ...
Read more
Help wanted in fight against AMR: World Pharma Association wants to see incentives – but also more regulation
Help wanted in the fight against AMR: World Pharma Association wants to see incentives - but also more regulation.
Read moreInterview – CNN – What might happen when a Covid-19 vaccine is ready?
Thomas Cueni, IFPMA Director-General, spoke to CNN about the challenges to be faced in the manufacturing of a COVID-19 vaccine on a large-scale and how the industry, as a whole, will respond to the challenges. 00:02 to 1:04 (Transcript of Thomas Cueni’s part) ANNA STEWART, CNN REPORTER (AS): At least, 100 COVID-19 vaccines are in development...
Read moreInnovation and equity: at the core of future pandemic responses
In this year’s edition of Health: A Political Choice – From Fragmentation to Integration, Thomas Cueni focuses on the lessons learned from COVID-19. When the next pandemic hits, the success of our response will depend on how well we react to the lessons learned from Covid-19. The world was ill prepared for the pandemic, costing millions of...
Read more
R&D-based biopharmaceutical industry welcomes UN Declaration on TB
New York, 26 September 2018 Statement by the International Federation of Pharmaceutical Manufacturers and Associations at the High Level Meeting of the General Assembly on ending Tuberculosis IFPMA congratulates the United Nations General Assembly in holding the first-ever high-level meeting on the fight against tuberculosis and welcomes the UN Political Declaration on TB. The global...
Read more3rd global Biopharma CEO / top execs virtual press briefing – COVID-19
IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D. The briefing was an opportunity to hear directly from the decision-makers.
Read more